Clinical trials: Pancreatic Ductal Adenocarcinoma (PDAC)
Stage I-II Pancreatic Ductal Adenocarcinoma (PDAC), Precise Prognostic and Predictive Signature
Precise Gene Signature for Predicting Outcomes in PDAC
The current TNM staging system is not sufficient for prediction of prognosis and cannot precisely identify the patients who are in greater need of adjuvant therapy in pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT05441189
- Testing
- Resection
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The Fourth Affiliated Hospital of Anhui Medical University
Pancreatic Ductal Adenocarcinoma, PDAC
Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer
The early diagnosis rate of pancreatic cancer is low and most patients rely on palliative chemotherapy. However, the clinical benefit and objective response rate (ORR) of patients with first-line chemotherapy are low.
- Trial name
- NCT05201729
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Pancreatic Ductal Adenocarcinoma, PDAC
Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer
The early symptoms of pancreatic cancer are not obvious, and the early diagnosis rate is low. For most patients with pancreatic cancer,palliative chemotherapy is the only choice .At present, The guidance of NCCN guidelines on the…
- Trial name
- NCT05168254
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC)
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in…
- Conditions
- Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT03811652
- Testing
- MEDI7247
- Where
- 3 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- MedImmune LLC
Pancreatic Ductal Adenocarcinoma (PDAC)
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
The purpose of this study is to see whether it is possible to give 8 doses of a combination of chemotherapy called FOLFIRINOX before surgery in subjects whose pancreas cancer can be removed with surgery.
- Trial name
- NCT02782182
- Testing
- FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Pancreatic Ductal Adenocarcinoma (PDAC)
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC
The proposal aims at determining whether liquid biopsy approaches are valid in the diagnosis of pancreatic cancer. Step1 will test 3 CTC isolation methods and analyse by flow cytometry the presence of onco-exosomes in the culture…
- Trial name
- PANC-CTC (NCT03032913)
- Testing
- Blood samples, Portal vein blood sample
- Where
- France
- Volunteers
- 52 people
- Sponsor
- University Hospital, Bordeaux